Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial
DISCOMS investigators, John R. Corboy, Robert J. Fox, Ilya Kister, Gary R. Cutter, Charity J. Morgan, Rebecca Seale, Eric Engebretson, Tarah Gustafson, Aaron E. Miller, Dennis Bourdette, Vijayshree Yadav, Andrew Goodman, Michael Racke, Robert Fallis, Carlo Tornatore, Myla Goldman, Meena Kannan, Subramaniam Sriram, Joseph BergerAnne Cross, Kottil Rammohan, Zongqi Xia, Thomas Leist, Sharon Lynch, Eric Klawiter, Lilyana Amezcua, James Bowen
Dive into the research topics of 'Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial'. Together they form a unique fingerprint.